Lead Product(s) : Trypsinogen,Chymotrypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma Hosts Corporate Update Call on Recent Progress and Positive Results
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 22, 2024
Lead Product(s) : Trypsinogen,Chymotrypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trypsinogen,Chymotrypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 15, 2023
Lead Product(s) : Trypsinogen,Chymotrypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection for a method to treat cancer stem cells.
Brand Name : PRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in the treatment of cancer.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 12, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 05, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by IV injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 26, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
Details : PRP (chymotrypsinogen) is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 18, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection, in advanced cancer patients suffering from solid tumors.
Brand Name : PRP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 02, 2022
Lead Product(s) : Chymotrypsinogen,Trypsinogen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?